Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency

Bradley J Monk; Robert L Coleman; Mansoor Raza Mirza

doi:10.1136/ijgc-2023-004478

Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency

Bradley J Monk^*, Robert L Coleman, Mansoor Raza Mirza

^*Corresponding author af dette arbejde

Afdeling for Kræftbehandling

6 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Vol/bind	33
Udgave nummer	6
Sider (fra-til)	1008-1009
Antal sider	2
ISSN	1048-891X
DOI	https://doi.org/10.1136/ijgc-2023-004478
Status	Udgivet - 5 jun. 2023

Adgang til dokumentet

10.1136/ijgc-2023-004478

Andre filer og links

Link to publication in Scopus

Citationsformater

Monk, B. J., Coleman, R. L., & Mirza, M. R. (2023). Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 33(6), 1008-1009. https://doi.org/10.1136/ijgc-2023-004478

Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency. / Monk, Bradley J; Coleman, Robert L; Mirza, Mansoor Raza.
I: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Bind 33, Nr. 6, 05.06.2023, s. 1008-1009.

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

Monk, BJ, Coleman, RL & Mirza, MR 2023, 'Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency', International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, bind 33, nr. 6, s. 1008-1009. https://doi.org/10.1136/ijgc-2023-004478

Monk BJ, Coleman RL, Mirza MR. Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2023 jun. 5;33(6):1008-1009. doi: 10.1136/ijgc-2023-004478

Monk, Bradley J ; Coleman, Robert L ; Mirza, Mansoor Raza. / Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer : opposing views of the US Food and Drug Administration and European Medicines Agency. I: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2023 ; Bind 33, Nr. 6. s. 1008-1009.

@article{36da25d9b43f4131bd1d5c1223f82ee3,

title = "Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency",

keywords = "Ovarian Cancer, Ovarian Neoplasms/drug therapy, United States/epidemiology, Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use, Neoplasm Recurrence, Local/drug therapy, Humans, Carcinoma, Ovarian Epithelial/drug therapy, Female, United States Food and Drug Administration",

author = "Monk, {Bradley J} and Coleman, {Robert L} and Mirza, {Mansoor Raza}",

year = "2023",

month = jun,

day = "5",

doi = "10.1136/ijgc-2023-004478",

language = "English",

volume = "33",

pages = "1008--1009",

journal = "International journal of gynecological cancer : official journal of the International Gynecological Cancer Society",

issn = "1048-891X",

publisher = "Lippincott Williams & Wilkins",

number = "6",

}

TY - JOUR

T1 - Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer

T2 - opposing views of the US Food and Drug Administration and European Medicines Agency

AU - Monk, Bradley J

AU - Coleman, Robert L

AU - Mirza, Mansoor Raza

PY - 2023/6/5

Y1 - 2023/6/5

KW - Ovarian Cancer

KW - Ovarian Neoplasms/drug therapy

KW - United States/epidemiology

KW - Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use

KW - Neoplasm Recurrence, Local/drug therapy

KW - Humans

KW - Carcinoma, Ovarian Epithelial/drug therapy

KW - Female

KW - United States Food and Drug Administration

UR - http://www.scopus.com/inward/record.url?scp=85159190781&partnerID=8YFLogxK

U2 - 10.1136/ijgc-2023-004478

DO - 10.1136/ijgc-2023-004478

M3 - Comment/debate

C2 - 37024238

SN - 1048-891X

VL - 33

SP - 1008

EP - 1009

JO - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

JF - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

IS - 6

ER -